2022 ASCO Annual Meeting*

Download All
June 3-7, 2022; Chicago, Illinois
Review slidesets and expert analyses of key data from the 2022 Clinical Oncology Annual Scientific Meeting!

Gastrointestinal Cancers

Capsule Summary Slidesets

With an extended follow-up of approximately 5 years, durable clinical benefit with no new safety concerns was observed with nivolumab ± ipilimumab for patients with MSI-H/dMMR metastatic CRC.

Released: June 9, 2022

Single-arm study shows preliminary activity of trastuzumab deruxtecan in advanced HER2-positive biliary tract cancers, including for HER2-low disease.

Released: June 9, 2022

Addition of radiotherapy to chemotherapy significantly improved the R0 resection rate specifically in patients who underwent surgery after chemoradiotherapy or chemotherapy alone but not in the overall population of patients with unresectable locally advanced pancreatic cancer.

Released: June 10, 2022

Improved survival with nivolumab + chemotherapy and nivolumab + ipilimumab vs chemotherapy alone in previously untreated patients with advanced esophageal squamous cell carcinoma and at least 1% PD-L1 expression assessed by either tumor cell staining or CPS.

Released: June 13, 2022

Compared with sorafenib treatment alone, addition of a single dose of tremelimumab to durvalumab in STRIDE and durvalumab monotherapy were associated with meaningful, patient-centered benefits for patients with unresectable hepatocellular carcinoma.

Released: June 6, 2022

In addition to a previously reported overall survival benefit, durvalumab + gemcitabine/cisplatin was associated with a trend toward longer time to deterioration in global health status/quality of life for patients with advanced biliary tract cancer vs placebo + gemcitabine/cisplatin.

Released: June 9, 2022

The phase III PARADIGM trial demonstrated superior overall survival with first-line panitumumab vs bevacizumab in combination with mFOLFOX6 in both the left-sided and overall mCRC populations with WT RAS.

Released: June 9, 2022

Intensification of first-line chemotherapy with mFOLFOXIRI in combination with panitumumab did not improve response rate, depth of response, or PFS in patients with RAS and BRAF wild-type mCRC.

Released: June 9, 2022

Among patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAFV600E-mutated primary tumors, FOLFOXIRI + bevacizumab was associated with superior outcomes vs FOLFOX or FOLFIRI + bevacizumab with an increase in manageable toxicity.

Released: June 10, 2022

Early data showed that among 14 patients with locally advanced, dMMR rectal cancer who completed treatment with the PD-1 inhibitor dostarlimab, all 14 achieved a clinical complete response, without the need for chemoradiotherapy or surgery.

Released: June 14, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings